Literature DB >> 22751123

Requirement of NEMO/IKKγ for effective expansion of KRAS-induced precancerous lesions in the pancreas.

H J Maier1, M Wagner, T G Schips, H H Salem, B Baumann, T Wirth.   

Abstract

Pancreatic carcinoma, a leading cause of cancer death, is thought to develop out of pancreatic intraepithelial neoplasia (PanIN). PanIN lesions have not yet attained the fully malignant phenotype, but show increased proliferation and dysplasia, and frequently bear an oncogenic KRAS mutation. Pancreatic cancer development is associated with increased activity of the transcription factor NF-κB. NEMO (IKKγ) is a subunit of the IKK complex essential for the activation of canonical NF-κB signaling and has been ascribed both oncogenic and tumor-suppressive roles in gastrointestinal tumors. Here, we wanted to address the function of NEMO in pancreatic tumorigenesis. We therefore conditionally ablated NEMO in a mouse model for pancreatic carcinoma based on the expression of oncogenic KRAS in pancreatic precursor cells. Mice were analyzed for PanIN lesions and for the activation of associated signaling pathways. NEMO ablation in the pancreas, while in itself not causing any overt pathology, led to a drastic (>93%) decrease in the prevalence of both low-grade and high-grade PanIN in 10-month-old mice expressing oncogenic KRAS. Also, the inflammatory and fibrotic response associated with KRAS action in the pancreas was virtually abolished, including expression of inflammatory cytokines and activation of the interleukin-6/STAT3 axis. Moreover, the activation of MAPK signaling, Notch and KLF4 signaling normally observed in KRAS-induced PanIN was strongly reduced or absent when NEMO was ablated. Our study suggests that NEMO, an IKK subunit necessary for canonical NF-κB activation, is dispensable for normal pancreatic development and function, but essential for the propagation of KRAS-induced PanIN lesions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22751123     DOI: 10.1038/onc.2012.272

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

Review 1.  Differentiation and Inflammation: 'Best Enemies' in Gastrointestinal Carcinogenesis.

Authors:  Nathan M Krah; L Charles Murtaugh
Journal:  Trends Cancer       Date:  2016-12

Review 2.  Regeneration and repair of the exocrine pancreas.

Authors:  L Charles Murtaugh; Matthew D Keefe
Journal:  Annu Rev Physiol       Date:  2014-10-24       Impact factor: 19.318

3.  Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma.

Authors:  Weiying Zhang; Nivedita Nandakumar; Yuhao Shi; Mark Manzano; Alias Smith; Garrett Graham; Swati Gupta; Eveline E Vietsch; Sean Z Laughlin; Mandheer Wadhwa; Mahandranauth Chetram; Mrinmayi Joshi; Fen Wang; Bhaskar Kallakury; Jeffrey Toretsky; Anton Wellstein; Chunling Yi
Journal:  Sci Signal       Date:  2014-05-06       Impact factor: 8.192

4.  KLF4 Is Essential for Induction of Cellular Identity Change and Acinar-to-Ductal Reprogramming during Early Pancreatic Carcinogenesis.

Authors:  Daoyan Wei; Liang Wang; Yongmin Yan; Zhiliang Jia; Mihai Gagea; Zhiwei Li; Xiangsheng Zuo; Xiangyu Kong; Suyun Huang; Keping Xie
Journal:  Cancer Cell       Date:  2016-03-14       Impact factor: 31.743

Review 5.  Inflammation as a driver and vulnerability of KRAS mediated oncogenesis.

Authors:  Shunsuke Kitajima; Rohit Thummalapalli; David A Barbie
Journal:  Semin Cell Dev Biol       Date:  2016-06-11       Impact factor: 7.727

6.  A novel pVHL-independent but NEMO-driven pathway in renal cancer promotes HIF stabilization.

Authors:  A M Nowicka; I Häuselmann; L Borsig; S Bolduan; M Schindler; P Schraml; M Heikenwalder; H Moch
Journal:  Oncogene       Date:  2015-10-26       Impact factor: 9.867

7.  The acinar differentiation determinant PTF1A inhibits initiation of pancreatic ductal adenocarcinoma.

Authors:  Nathan M Krah; Jean-Paul De La O; Galvin H Swift; Chinh Q Hoang; Spencer G Willet; Fong Chen Pan; Gabriela M Cash; Mary P Bronner; Christopher Ve Wright; Raymond J MacDonald; L Charles Murtaugh
Journal:  Elife       Date:  2015-07-07       Impact factor: 8.140

8.  c-Rel is a critical mediator of NF-κB-dependent TRAIL resistance of pancreatic cancer cells.

Authors:  C Geismann; F Grohmann; S Sebens; G Wirths; A Dreher; R Häsler; P Rosenstiel; C Hauser; J-H Egberts; A Trauzold; G Schneider; B Sipos; S Zeissig; S Schreiber; H Schäfer; A Arlt
Journal:  Cell Death Dis       Date:  2014-10-09       Impact factor: 8.469

9.  RelA regulates CXCL1/CXCR2-dependent oncogene-induced senescence in murine Kras-driven pancreatic carcinogenesis.

Authors:  Marina Lesina; Sonja Maria Wörmann; Jennifer Morton; Kalliope Nina Diakopoulos; Olga Korneeva; Margit Wimmer; Henrik Einwächter; Jan Sperveslage; Ihsan Ekin Demir; Timo Kehl; Dieter Saur; Bence Sipos; Mathias Heikenwälder; Jörg Manfred Steiner; Timothy Cragin Wang; Owen J Sansom; Roland Michael Schmid; Hana Algül
Journal:  J Clin Invest       Date:  2016-07-25       Impact factor: 14.808

10.  The 'N-factors' in pancreatic cancer: functional relevance of NF-κB, NFAT and Nrf2 in pancreatic cancer.

Authors:  A Arlt; H Schäfer; H Kalthoff
Journal:  Oncogenesis       Date:  2012-11-26       Impact factor: 7.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.